7th TCR-Based Therapies Summit [05/18/26]

The past few years for the TCR community have been dynamic. Approvals have signalled a viable path to commercialization, while a wave of company closures highlight the deep-rooted challenges in the current development processes. The message is clear: success is not guaranteed at approval. Addressing manufacturing costs, durability and long-term commercial viability is now mission critical for developers of TCR-based cell and biologic therapies.

Spanning the full therapeutic landscape, including TCR-T, TCR mimetics, TCR-TCEs and TCR bispecifics, the 7th TCR-Based Therapies Summit cuts through the noise to focus exclusively on the challenges most acutely impacting the TCR field today. Connect with and hear directly from senior leaders driving progress at the forefront of the field, including C-suite leaders at Immunocore, Immatics, T-knife Therapeutics, Anocca, Zelluna Immunotherapy, Enara Bio, Marengo Therapeutics, and 3T Biosciences.

With the foundations now in place, join us in empowering the community to shape a more durable, scalable, and commercially robust future for TCR-based therapies.

URLs:

Tickets: https://go.evvnt.com/3452417-2?pid=5248

Brochure: https://go.evvnt.com/3452417-3?pid=5248

Prices:

Drug Developer Pricing - Full Access Pass: Conference + Workshop: USD 4397.00,

Drug Developer Pricing - Conference Only: USD 3099.00,

Academic and Not-For Profit Pricing - Full Access Pass: Conference + Workshop: USD 3797.00,

Academic and Not-For Profit Pricing - Conference Only: USD 2699.00,

Service and Solution Provider Pricing - Full Access Pass: Conference + Workshop: USD 5297.00,

Service and Solution Provider Pricing - Conference Only: USD 3299.00

Speakers: Tao Wang, Associate Professor, Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Cassian Yee, Director, T-Cell-Based Therapies (ProTCT), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Sarah Leonard, Vice President, Preclinical Development, TCR-Based Therapeutics, T-Cypher Bio, Mollie Jurewicz, Director, TCR and Autoimmune Discovery, TScan Therapeutics, Emilie Gauthy, Head, CMC, Zelluna Immunotherapy, David DiLillo, Senior Director, Immuno-Oncology, Regeneron Pharmaceuticals, Gene Uenishi, Associate Director, Discovery, GentiBio, Ricard Masia, Senior Director, Translational Medicine, Crossbow Therapeutics, Serena Stadler, Senior Scientist, Captain T Cell, Qi Zhao, Principal Scientist, BioNTech, Luise Weigand, Chief Scientific Officer, Zelluna Immunotherapy, Annelise Vuidepot, Chief Technology Officer, Immunocore, Ke Liu, Chief Development Officer, Marengo Therapeutics, Zhen Su, Chief Executive Officer and Director, Marengo Therapeutics Inc., Rachel Abbott, Chief Executive Officer, Pan Cancer T, Peggy Sotiropoulou, Chief Scientific Officer, T-knife Therapeutics, Cedrik Britten, Chief Medical Officer, Immatics, Cheng Liu, President and Chief Executive Officer, Eureka Therapeutics, Joseph Dukes, Chief Scientific Officer, Enara Bio, Reagan Jarvis, Chief Executive Officer and Co-Founder, Anocca, Stefan Scherer, Chief Executive Officer and President, 3T Biosciences

7th TCR-Based Therapies Summit

Share this event

Sponsored events

Revolutionary Beginnings with George and Martha Washington